Last reviewed · How we verify
COVID-19 convalescent plasma — Competitive Intelligence Brief
phase 2
Infectious Diseases
Biologic
Live · refreshed every 30 min
Target snapshot
COVID-19 convalescent plasma (COVID-19 convalescent plasma) — Lifefactors Zona Franca, SAS. COVID-19 convalescent plasma is a treatment that uses antibodies from recovered patients to help the body fight off the SARS-CoV-2 virus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| COVID-19 convalescent plasma TARGET | COVID-19 convalescent plasma | Lifefactors Zona Franca, SAS | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- COVID-19 convalescent plasma CI watch — RSS
- COVID-19 convalescent plasma CI watch — Atom
- COVID-19 convalescent plasma CI watch — JSON
- COVID-19 convalescent plasma alone — RSS
Cite this brief
Drug Landscape (2026). COVID-19 convalescent plasma — Competitive Intelligence Brief. https://druglandscape.com/ci/covid-19-convalescent-plasma. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab